Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Purple Biotech Ltd - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PPBT
Nasdaq
8731
https://purple-biotech.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Purple Biotech Ltd - ADR
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
- Apr 25th, 2024 11:00 am
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
- Mar 28th, 2024 11:00 am
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
- Mar 14th, 2024 11:30 am
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
- Mar 5th, 2024 12:55 pm
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
- Feb 27th, 2024 12:00 pm
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
- Feb 13th, 2024 12:00 pm
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
- Feb 1st, 2024 12:30 pm
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
- Dec 20th, 2023 1:05 pm
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
- Dec 14th, 2023 11:50 am
Purple Biotech Reports Third Quarter 2023 Financial Results
- Nov 21st, 2023 11:50 am
Purple Biotech Fortifies NT219 Patent Protection
- Nov 2nd, 2023 11:00 am
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
- Oct 19th, 2023 7:55 pm
Purple Biotech Announces $5 Million Registered Direct Offering
- Oct 17th, 2023 12:00 pm
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
- Oct 6th, 2023 11:50 am
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
- Oct 3rd, 2023 11:50 am
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
- Sep 21st, 2023 12:00 pm
Purple Biotech Reports Second Quarter 2023 Financial Results
- Aug 22nd, 2023 1:29 pm
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
- Jul 11th, 2023 12:15 pm
Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update
- May 16th, 2023 8:00 pm
Scroll